The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Central role for PICALM in amyloid-β blood-brain barrier transcytosis and clearance
Open accessAbstract
PICALM is a highly validated genetic risk factor for Alzheimer's disease (AD). We found that reduced expression of PICALM in AD and murine brain endothelium correlated with amyloid-β (Aβ) pathology and cognitive impairment. Moreover, Picalm deficiency diminished Aβ clearance across the murine blood-brain barrier (BBB) and accelerated Aβ pathology in a manner that was reversible by endothelial PICALM re-expression. Using human brain endothelial monolayers, we found that PICALM regulated PICALM/clathrin-dependent internalization of Aβ bound to the low density lipoprotein receptor related protein-1, a key Aβ clearance receptor, and guided Aβ trafficking to Rab5 and Rab11, leading to Aβ endothelial transcytosis and clearance. PICALM levels and Aβ clearance were reduced in AD-derived endothelial monolayers, which was reversible by adenoviral-mediated PICALM transfer. Inducible pluripotent stem cell-derived human endothelial cells carrying the rs3851179 protective allele exhibited higher PICALM levels and enhanced Aβ clearance. Thus, PICALM regulates Aβ BBB transcytosis and clearance, which has implications for Aβ brain homeostasis and clearance therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Similarly, several genes reported to be involved in Aβ catabolism, such as RAB5A, RAB11A, CLU, and LRP2 (49–53), were also down-regulated in AD monocytes, suggesting the impaired Aβ catabolism in AD monocytes.”
From Understanding monocyte-driven neuroinflammation in Alzheimer’s disease using human cortical organoid microphysiological systems (2025) · cites this paper as [51]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“PICALM is enriched in the endothelium of human cerebral vessels including capillaries, but is downregulated in AD patients (683).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [683]
The cited source says what the claim attributes to it.
In the citing paper
“PICALM controls receptor internalization and subsequent intracellular trafficking (683), via R-SNARE-mediated fusion of clathrin-coated vesicles with endosomes (411).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [683]
The cited source says what the claim attributes to it.
In the citing paper
“Specifically, LRP1 facilitates clathrin-dependent, receptor-mediated endothelial endocytosis of A 𝛃 at the abluminal membrane of the BBB, which requires phosphatidylinositol binding clathrin assembly protein (PICALM) (683).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [683]
The cited source says what the claim attributes to it.
In the citing paper
“PICALM guides transendothelial trafficking of endocytotic A 𝛃 -containing vesicles to Rab5, and then to Rab11 small GTPase leading to exocytosis of A 𝛃 across the luminal membrane of the BBB into the blood (683).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [683]
The cited source says what the claim attributes to it.
In the citing paper
“As shown in the Picalm + / -; APP Swe mice, diminished PICALM levels at the BBB accelerate amyloid pathology and behavioral deficits, which can be ameliorated by endothelial re-expression of Picalm using an adeno-associated virus (AAV) (683).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [683]
The cited source says what the claim attributes to it.
In the citing paper
“Endothelial cells derived from human iPSCs carrying homozygous protective rs3851179 A alleles exhibited increased PICALM expression and improved transvascular clearance of A 𝛃 across human BBB in vitro, when compared with isogenic cells from iPSCs carrying homozygous risk rs3851179 G alleles (683).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [683]
The cited source says what the claim attributes to it.
In the citing paper
“Although most of the PICALM single nucleotide variants (SNPs) associated with late-onset AD are located outside of the coding regions (683), the risk alleles of rs3851179 (236) and rs10792832 (344) lead to lower expression of PICALM isoform 2 in the frontal and temporal cortex in the human brain on the expression quantitative trait loci (eQTLs) (586), indicating that lower PICALM levels may”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [683]
The cited source says what the claim attributes to it.
In the citing paper
“These functions are central to its role in the clearance of both tau through autophagy (423) and A 𝛃 via transvascular transport across the BBB (683).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [683]
The cited source says what the claim attributes to it.
In the citing paper
“The brain-to-blood transfer of monomeric Aβ is highly dependent on low-density lipoprotein receptor-related protein 1 (LRP1) [13, 14], which in brain endothelium is primarily located at the abluminal side [13, 15].”
From PCSK9 acts as a key regulator of Aβ clearance across the blood–brain barrier (2022) · cites this paper as [15]
The cited source says what the claim attributes to it.
In the citing paper
“More recently, PICALM has been described in vitro and in vivo to participate to Aβ transcytosis and clearance at the BBB through clathrin-dependent internalisation of Aβ after its binding to the LDLR-related protein-1 [157].”
From The new genetic landscape of Alzheimer’s disease: from amyloid cascade to genetically driven synaptic failure hypothesis? (2019) · cites this paper as [157]
In the citing paper
“For previously reported loci, applying the same prioritization approach highlights several genes, as described in Fig. 2, some of which are involved in APP metabolism (FERMT2, PICALM) or tau toxicity (BIN1, CD2AP, FERMT2, CASS4, PTK2B)98–101.”
From Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing (2019) · cites this paper as [101]
In the citing paper
“Several genes encoding proteins intimately associated with the endothelium and Aβ clearance are highly validated AD risk factors, such as APOEε4, PICALM, and CLU [50, 51].”
From Systems-based proteomics to resolve the biology of Alzheimer’s disease beyond amyloid and tau (2021) · cites this paper as [51]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: Pericyte loss influences Alzheimer-like neurodegeneration in mice
Sagare, A. P., Bell, R. D., Zhao, Z., Ma, Q., Winkler, E. A., Ramanathan, A., & Zlokovic, B. V. (2013) · Nature Communications · doi:10.1038/ncomms3932 · Cited by 589
Self-citationRetractedThe Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
Querfurth, H. W., & LaFerla, F. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0909142 · Cited by 4,569
Meta-Analysis of 74,046 Individuals Identifies 11 New Susceptibility Loci for Alzheimer’s Disease
(EADI), E. A. D. I., Lambert, J.-C., (GERAD), G. A. E. R. I. A. D., Alzheimer's Disease Genetic Consortium (ADGC), (CHARGE), C. F. H. A. A. R. I. G. E., Ibrahim-Verbaas, C. A., Harold, D., Naj, A. C., Sims, R., Bellenguez, C., et al. (2013) · Nature Genetics · doi:10.1038/ng.2802 · Cited by 4,336
Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice
Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., & Cole, G. (1996) · Science · doi:10.1126/science.274.5284.99 · Cited by 4,210
Rab GTPases as coordinators of vesicle traffic
Stenmark, H. (2009) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2728 · Cited by 3,413
Harold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326
Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders
Zlokovic, B. V. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3114 · Cited by 2,969
Flagged first, then by citations
Cited by
Sorted by citations
Items 301–400 of 410
Arispe, N. J., & Maio, A. D. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180161 · Cited by 11
Takatori, S., & Tomita, T. (2018) · Advances in experimental medicine and biology · doi:10.1007/5584_2018_218 · Cited by 10
Wickstead, E. S., Irving, M. A., Getting, S. J., & McArthur, S. (2021) · FEBS Journal · doi:10.1111/febs.15861 · Cited by 10
Biphasic Effects of Ethanol Exposure on Waste Metabolites Clearance in the CNS
Cheng, Y., Ma, X., Belfield, K. D., & Haorah, J. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02379-w · Cited by 12
S, H. S. G. N., Prasanna, V. L., Satish, K. S., Yergolkar, A. V., Krishnamurthy, M., Rajalekshmi, S. G., Radhika, K., & Burri, R. R. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101421 · Cited by 10
Tijms, B. M., Vromen, E. M., Mjaavatten, O., Holstege, H., Reus, L. M., van der Lee, S., Wesenhagen, K. E., Lorenzini, L., Vermunt, L., Venkatraghavan, V., et al. (2023) · doi:10.1101/2023.05.10.23289793 · Cited by 10
Mazura, A. D., & Pietrzik, C. U. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041268 · Cited by 9
“The high transcytosis rate of LRP1 and the tightly regulated low brain microvascular protein levels [92], which are significantly reduced with age or in AD [97–99], might reflect the significance and performance of LRP1 transcytosis at the BBB.”
BackgroundTian, C., Ao, Z., Cerneckis, J., Cai, H., Chen, L., Niu, H., Takayama, K., Kim, J., Shi, Y., Gu, M., et al. (2025) · Science Advances · doi:10.1126/sciadv.adu2708 · Cited by 9
Self-citationWu, Z., Yang, Y., Song, Z., Ma, M., Feng, M., Liu, Y., Xing, H., Chang, Y., & Dai, H. (2022) · Brain Sciences · doi:10.3390/brainsci12121681 · Cited by 8
Haploinsufficiency and Alzheimer’s Disease: The Possible Pathogenic and Protective Genetic Factors
Bagyinszky, E., & An, S. S. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252211959 · Cited by 10
Risk of Alzheimer's disease in Down syndrome: Insights gained by multi‐omics
Qu, H., Liu, Y., Connolly, J. J., Mentch, F. D., Kao, C., & Hakonarson, H. H. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14604 · Cited by 9
Li, Y., Zhang, J., Ma, B., Yu, W., Xu, M., Luan, W., Yu, Q., Zhang, L., Rong, R., Fu, Y., et al. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124786 · Cited by 10
Shen, G., Hu, S. X., Zhao, Z., Zhang, L., & Ma, Q. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168966 · Cited by 8
Self-citationNguyen, D. L., Okolicsanyi, R. K., & Haupt, L. M. (2024) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2024.103936 · Cited by 9
Shanmugam, N. K. N., Zamudio, F., Kumar, D. K. V., Barrett, K. A., VanDoren, R., Chen, M., Barr, O. M., Watson, S., Lin, C., Eimer, W. A., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70292 · Cited by 8
DKK3-LRP1 complex and a chemical inhibitor regulate Aβ clearance in models of Alzheimer’s disease
Yang, R., Wang, L., Li, Y., Zhu, J., Wang, J., Schlessinger, D., & Sima, J. (2025) · Science Advances · doi:10.1126/sciadv.adz2099 · Cited by 8
Genome-Wide Association Study Identifies SLAMF1 Affecting the Rate of Memory Decline
Chen, S.-D., Initiative, O. B. O. A. D. N., Li, H., Shen, X., Li, J., Xu, W., Huang, Y., Tan, L., Dong, Q., & Yu, J. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-191214 · Cited by 8
Astrocytic S100B, Blood-Brain Barrier and Neurodegenerative Diseases
Krishnan, A., Wu, H., & Venkataraman, V. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.92146 · Cited by 8
RNA processing in neurological tissue: development, aging and disease
Szeto, R. A., Tran, T. H., Truong, J., Negraes, P. D., & Trujillo, C. A. (2020) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2020.09.004 · Cited by 8
Ning, H., Zhang, T., Zhou, X., Liu, L., Shang, C., Qi, R., & Ma, T. (2022) · Gene · doi:10.1016/j.gene.2021.146164 · Cited by 8
Breuza, L., Arighi, C. N., Argoud‐Puy, G., Casals‐Casas, C., Estreicher, A., Famiglietti, M. L., Georghiou, G. P., Gos, A., Gruaz-Gumowski, N., Hinz, U. G., et al. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200206 · Cited by 8
Lizcano, F., Sanabria, D., & Aviles, E. (2025) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2025.1622186 · Cited by 8
Zheng, Y., Xu, W., Suo, Z., Qu, Y., Lin, L., Zhang, E., Han, D., Wu, M., Hongyi, L. I., Zheng, H., et al. (2025) · Journal of Neuroinflammation · doi:10.1186/s12974-025-03566-5 · Cited by 8
Peppercorn, K., Kleffmann, T., Jones, O. D., Hughes, S. M., & Tate, W. P. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.858524 · Cited by 8
Crosstalk between peripheral immunity and central nervous system in Alzheimer’s disease
Yang, H.-C., Qin, Q., Wang, M., Yin, Y., Li, R., & Tang, Y. (2023) · Cellular Immunology · doi:10.1016/j.cellimm.2023.104743 · Cited by 9
Kong, F., Wu, T., Dai, J., Cai, J., Zhai, Z., Zhu, Z., Xu, Y., & Sun, T. (2024) · PLoS ONE · doi:10.1371/journal.pone.0295008 · Cited by 8
Guizar, P., Abdalla, A. L., Monette, A., Davis, K., Caballero, R. E., Niu, M., Liu, X., Ajibola, O., Murooka, T. T., Chen, L., et al. (2024) · iScience · doi:10.1016/j.isci.2024.110131 · Cited by 7
Ramachandran, S. S., Coffin, S. L., Tang, T., Jobaliya, C., Spengler, R. M., & Davidson, B. L. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw317 · Cited by 7
Guebel, D. V., Torres, N. V., & Acebes, Á. (2021) · Biology Open · doi:10.1242/bio.057950 · Cited by 6
Advances in brain barriers and brain fluid research and news from Fluids and Barriers of the CNS
Drewes, L. R., Jones, H. C., & Keep, R. F. (2015) · Fluids and Barriers of the CNS · doi:10.1186/s12987-016-0026-1 · Cited by 7
Advances in Research on Meningeal Lymphatic Vessels in Central Nervous System Diseases
Shen, H., Zhu, B., Qian, Y., Jin, J., Zhou, J., Peng, G., & Mo, J. (2024) · Journal of Craniofacial Surgery · doi:10.1097/scs.0000000000010872 · Cited by 7
Kordi, R., Andrews, T. J., & Hicar, M. D. (2025) · Virology · doi:10.1016/j.virol.2025.110523 · Cited by 6
Avetisyan, A. V., Balasanyants, S. M., Simonyan, R. A., Koroev, D. O., Kamynina, A. V., Zinovkin, R. A., Бобкова, Н. В., & Volpina, O. M. (2020) · Neurochemistry International · doi:10.1016/j.neuint.2020.104799 · Cited by 6
Zhang, C., Ma, J.-J., Li, X., Yan, H., Gui, Y., Yan, Z.-X., You, M., & Zhang, P. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1565382 · Cited by 10
Advances in Alzheimer’s disease: mechanistic insights and therapeutic targets
Jia, Y.-J., Ge, Y., Li, B., Yang, Y., Chen, H., Liu, J., Guo, J., Yu, J., Ye, K., Wang, J., et al. (2026) · Science China Life Sciences · doi:10.1007/s11427-025-2991-7 · Cited by 6
Kim, H. Y., Kwon, J. A., Kang, T., & Choi, I. (2017) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2017.01.004 · Cited by 5
Tyndall, A. V., Longman, R. S., Sajobi, T. T., Parboosingh, J. S., Drogos, L. L., Davenport, M. H., Eskes, G. A., Hogan, D. B., Hill, M. D., & Poulin, M. J. (2020) · Frontiers in Integrative Neuroscience · doi:10.3389/fnint.2020.571683 · Cited by 6
Liu, Y., Initiative, A. D. N., Wang, X.-J., Tan, L., Tan, C., & Xu, W. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230516 · Cited by 5
Wang, J., Chen, J., Chen, J., Xia, K., Yuan, P., Zhou, X., Wang, R., Yu, C., Li, Y., Shi, K., et al. (2025) · ACS Nano · doi:10.1021/acsnano.5c08255 · Cited by 4
Transport pathways across the blood-brain barrier for waste clearance and drug delivery
Gröbner, L. S., & Pietrzik, C. U. (2026) · Fluids and Barriers of the CNS · doi:10.1186/s12987-026-00812-7 · Cited by 4
Kim, D., Gim, J., Mishra, A., Lee, K., Cho, Y., & Kim, H. (2017) · Genes & Genomics · doi:10.1007/s13258-017-0524-9 · Cited by 4
Flotho, M., Yang, A. C., Kern, F., Graf, S., Diks, I. F., Shin, H., Zera, K. A., Berdnik, D., Agam, M. R., Channappa, D., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.25.672093 · Cited by 4
Wu, Z., Chen, J., Liu, Y., Yang, Y., Feng, M., Dai, H., & Initiative, T. A. D. N. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-03953-8 · Cited by 3
Suche nach Risikogenen bei der Alzheimer-Erkrankung
Karaca, I., Wagner, H., & Ramı́rez, A. (2017) · Der Nervenarzt · doi:10.1007/s00115-017-0354-7 · Cited by 3
Improving mouse models for the study of Alzheimer's disease
Reagan, A. M., Onos, K. D., Heuer, S. E., Sasner, M., & Howell, G. R. (2022) · Current topics in developmental biology/Current Topics in Developmental Biology · doi:10.1016/bs.ctdb.2021.12.005 · Cited by 5
Al-Ahmad, A. J. (2023) · Handbook of experimental pharmacology · doi:10.1007/164_2023_645 · Cited by 3
Feleke, R., Jogaudaite, S., Velentza‐Almpani, E., Yeung-Yeung, L., Clode, D., Ko, J. H., Shin, B., Matthews, S., Otero‐Jimenez, M., Wojewska, M. J., et al. (2025) · Acta Neuropathologica · doi:10.1007/s00401-025-02869-4 · Cited by 4
Two peptides targeting endothelial receptors are internalized into murine brain endothelial cells
Hudecz, D., Sigurdardóttir, S. B., Christensen, S. C., Hempel, C., Urquhart, A. J., Andresen, T. L., & Nielsen, M. S. (2021) · PLoS ONE · doi:10.1371/journal.pone.0249686 · Cited by 3
Tian, C., Ao, Z., Cerneckis, J., Cai, H., Chen, L., Niu, H., Takayama, K., Kim, J., Shi, Y., Gu, M., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.02.16.638539 · Cited by 3
Self-citationYata, V. K., Das, O. P., Dansana, J., Gadtya, A., Meher, B. R., Bukke, S. P. N., & Kolliputi, N. (2025) · Frontiers in Artificial Intelligence · doi:10.3389/frai.2025.1709505 · Cited by 2
Endocytic scaffolds at the crossroads of Alzheimer’s disease and neuronal aging
Shergill, J. K., & Tehran, D. A. (2026) · Biological Chemistry · doi:10.1515/hsz-2025-0250 · Cited by 3
Barriers of the CNS and Their Contribution to Drug-Resistant Epilepsy
Díaz-Coránguez, M., Auzmendi, J., Fuentes-Mejía, M., Cosme, T. M., Lazarowski, A., & Rocha, L. (2024) · AAPS introductions in the pharmaceutical sciences · doi:10.1007/978-3-031-62604-3_8 · Cited by 2
Beatty, A. E., Barnes‐Tompkins, T. M., Long, K. M., & Tobiansky, D. J. (2024) · The Anatomical Record · doi:10.1002/ar.25583 · Cited by 2
Advances in Retinal Imaging: Retinal Amyloid Imaging
Koronyo‐Hamaoui, M., Doustar, J., Oviatt, M., Black, K. L., & Koronyo, Y. (2020) · Springer eBooks · doi:10.1007/978-3-030-26269-3_6 · Cited by 4
Neuronal functions of clathrin-associated endocytic sorting adaptors – from molecules to disease
Kononenko, N. L., & Haucke, V. (2020) · e-Neuroforum · doi:10.1515/nf-2020-0023 · Cited by 2
Zhu, B., Li, L., Zhang, L., Yang, S., Tian, Y., Guo, S., Zhang, W., & Zhao, Z. (2018) · Metabolic Brain Disease · doi:10.1007/s11011-018-0291-6 · Cited by 2
Self-citationBin, Y., Zhu, Q., Li, M., & Xia, J. (2019) · IEEE Access · doi:10.1109/access.2019.2935515 · Cited by 3
Leite, D. M., Seifi, M., Ruiz‐Pérez, L., Nguemo, F., Plomann, M., Swinny, J. D., & Battaglia, G. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.07.12.199869 · Cited by 2
Zhao, G., Cui, B., Lu, Y., Ma, K., Gao, X., She, X., Zhu, Y., Ji, X., Yang, H. M., & Yang, H. (2026) · Biomolecules · doi:10.3390/biom16020200 · Cited by 1
Aderibigbe, O., Wood, L. B., & Margulies, S. S. (2026) · Acta Neuropathologica Communications · doi:10.1186/s40478-026-02260-8
Burdman, G., Akkaoui, J., Colon, N., Perez, A. G., & Lakshmana, M. K. (2026) · Neurology International · doi:10.3390/neurolint18030050 · Cited by 2
Zheng, H., Li, Q., Luo, H., Yuan, Y., Zhang, N., Lu, Y., Duan, S., Zhong, J., Hb, Z., Liu, C. G., et al. (2026) · Advanced Science · doi:10.1002/advs.76761 · Cited by 1
Is amyloid beta peptide a driver of inflammaging?
Kechko, O. I., Moskalev, A. A., Franceschi, C., Mitkevich, V. A., & Makarov, A. А. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103280 · Cited by 1
Alzheimer’s disease related genes during primate evolution
Kim, D., Gim, J., Kim, K. H., Han, C. W., Jang, S. B., & Kim, H. (2017) · Genes & Genomics · doi:10.1007/s13258-017-0584-x · Cited by 2
Meta-analysis on the association between rs11868035, rs823144, rs3851179 and Parkinson's disease
Sun, J., Deng, L., Zhu, H., Liu, M., Lyu, R., Lai, Q., & Zhang, Y. (2021) · Meta Gene · doi:10.1016/j.mgene.2021.100949 · Cited by 1
Yan, Y., Chen, R., Kang, H., Tan, Y. J., Tiwari, A., Ma, S., Wen, Z., Zhong, X. Y., & Li, B. (2025) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1013303 · Cited by 1
The relationship between the blood-brain barrier, degenerative neuropathy, and oxidative stress
Fisher, D., & Alamu, O. A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-817780-8.00002-5 · Cited by 1
Пономарева, Н. В., Андреева, Т. В., Fokin, V. F., Illarioshkin, S. N., & Rogaev, E. I. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-815868-5.00003-7 · Cited by 1
Wang, Z., Sharda, N., Omtri, R. S., Li, L., & Kandimalla, K. K. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.11.17.516996 · Cited by 1
Chen, J., Xiang, P., Duro‐Castaño, A., Cai, H., Guo, B., Liu, X., Yu, Y., Lui, S., Luo, K., Ke, B., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.05.06.592767 · Cited by 1
Adaptor protein 2 sigma subunit ( AP2S1 ) variants associated with neurodevelopmental disordersPreprint
Stevenson, M., Bayliss, A. L., Stokes, V. J., English, K. A., Kooblall, K. G., Fischer, R., Heilig, R., Vendrell, I., Albers, M. E. W. A., Bartos, M. N., et al. (2024) · medRxiv · doi:10.1101/2024.07.22.24310683 · Cited by 1
Shared Genetic Architecture Between Kidney Function and Alzheimer Disease Across AncestriesPreprint
Yang, D., Yang, Y., Ray, N. R., Li, M., Benchek, P. H., Crawford, D. C., O’Toole, J. F., Sedor, J. R., Reitz, C., Lynn, A., et al. (2026) · medRxiv · doi:10.64898/2026.04.04.26350158 · Cited by 1
The Complex Pathways to Mechanism-Based Therapeutics in Alzheimer’s Disease
Selkoe, D. J. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802173-6.00001-0
Burt, A. L., Thomas, R. S., Dunstan, M. L., Sims, R., & Williams, J. H. (2016) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.06.891
Genetic and lifestyle influences on memory, brain structure, and dementia
Ferencz, B. (2017) · Figshare
Gonzalez, B. L. (2016) · eScholarship (California Digital Library)
Genetic Risk Factors for Complex Forms of Alzheimer’s Disease
Bellenguez, C., & Lambert, J. (2018) · Springer eBooks · doi:10.1007/978-3-319-72938-1_4
Blood-Brain Barrier–Targeted Nanotechnological Advances
Obulesu, M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816412-9.00005-7
Fernandez, F., & Andrews, J. L. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-815854-8.00009-4
Pathogénie et physiopathologie de la maladie d’Alzheimer
Nicole, O. (2022) · Elsevier eBooks · doi:10.1016/b978-2-294-76331-1.00002-1 · Cited by 1
Guo, B., Chang, J., & Abumaria, N. (2024) · Stress and Brain · doi:10.26599/sab.2024.9060001
Unveiling the Mysteries of the Blood-brain Barrier: The Problem of the Brain/spinal Pharmacotherapy
Walia, A., Kaur, A., Singh, R., Rani, N., & Swami, R. (2024) · Central Nervous System Agents in Medicinal Chemistry · doi:10.2174/0118715249297247240813104929
李, 越. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.154977
Imaging Alzheimer’s Retinopathy
Gaire, B. P., Koronyo, Y., Shi, H., Rentsendorj, A., Dumitrascu, O. M., Vit, J., Doustar, J., Black, K. L., Fuchs, D.-T. S., & Koronyo‐Hamaoui, M. (2025) · Springer eBooks · doi:10.1007/978-3-031-72156-4_6
ENDOTHELIAL GLYCOCALYX DEGRADATION IN CEREBRAL EDEMA: PROMISING OPPORTUNITIES FOR INTENSIVE CARE
Massorov, V. V., Bykov, Y. V., Baturin, V. A., & Vorobyova, A. P. (2025) · Avicenna Bulletin · doi:10.25005/2074-0581-2025-27-2-416-427
Chen, J., Yu, S., Xie, G., Feng, R., Cui, W., Cai, R., Tang, K., Zhang, N., & Wu, Y.-X. (2025) · The Analyst · doi:10.1039/d5an00544b
Yu, R., Li, Y., Cao, Y., Kong, Z., Zhou, Y., Hou, B., & Xie, A. (2025) · BMC Medical Genomics · doi:10.1186/s12920-025-02280-8
Raut, S., Patel, R., & Al-Ahmad, A. J. (2021) · Figshare · doi:10.6084/m9.figshare.13545554
Systemic Amyloid-β Metabolism in Alzheimer’s Disease
Dong-yu, F., Wang, J., Gu, B. J., Masters, C. L., & Wang, Y. (2026) · Springer eBooks · doi:10.1007/978-981-95-5222-1_7
Ando, K., Lopez‐Gutierrez, L., Mansour, S., Yilmaz, Z., Dauphinot, L., Verheijen, J., Fontaine, G., Quintanilla‐Sánchez, C., Aydin, E., Doeraene, E., et al. (2026) · Cells · doi:10.3390/cells15030235
Nasciben, L. B., Wang, L., Xu, W., Ramírez, A. M., Moura, S., Lu, L., Liu, X., Rajabli, F., Celis, K., Gearing, M., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.14.705927
Picalm coordinates clathrin-mediated endocytosis and actin remodeling during myogenesis
Gaugel, J., Haacke, N., Kuropka, B., Jähnert, M., Rominger, J., Jonas, W., Speckmann, T., Rausch, N., Kleinert, M., Weigert, C., et al. (2026) · Molecular Metabolism · doi:10.1016/j.molmet.2026.102351
Implication des polynucléaires neutrophiles au cours de la maladie d’Alzheimer et des tauopathies
Dong, Y. (2018) · theses.fr (ABES) · doi:10.70675/0542df04zd02ez4a58za844z605f237e8f0b
Valverde, A. (2020) · theses.fr (ABES) · doi:10.70675/f1b70734zf4e3z4870z8fbdz950d831642a7
Meng, N., Li, C., Bai, F., Zhang, J., Li, X., Zhang, J., Zhang, C., Fu, J., Fu, J., & An, L. (2026) · Journal of Advanced Research · doi:10.1016/j.jare.2026.04.062
Metadata
- Authors
- Zhao, Z., Sagare, A. P., Ma, Q., Halliday, M. R., Kong, P., Kisler, K., Winkler, E. A., Ramanathan, A., Kanekiyo, T., Bu, G., Owens, N. C., Rege, S. V., Si, G., Ahuja, A., Zhu, D., Miller, C. A., Schneider, J. A., Maeda, M., Maeda, T., Sugawara, T., Ichida, J. K., & Zlokovic, B. V.
- Affiliations
- University of Southern California (US)
- Mayo Clinic (US)
- North Carolina Agricultural and Technical State University (US)
- Rush University Medical Center (US)
- Brigham and Women's Hospital (US)
- ORCID
- Venue
- Nature Neuroscience
- Published
- 2015-05-25
- Volume
- 18
- Issue
- 7
- Pages
- 978-987
- ISSN
- 1097-6256 (ISSN-L)
- 1546-1726
- PMC
- PMC4482781
- OpenAlex
- W1516940938
- Cited by
- 410
- References
- 59
- Citations by year
- 2026: 26 · 2025: 24 · 2024: 32 · 2023: 36 · 2022: 31 · 2021: 36 · 2020: 50 · 2019: 48 · 2018: 50 · 2017: 30 · 2016: 33 · 2015: 14
- FWCI
- 31.19
- Type
- journal article
- Language
- en
- Update notices
- correction (2023-11-20)
- Open access
- bronze
- doi.org
- Licence
- Locations
- Nature Neuroscience (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- The Scholars Repository - LLU (Loma Linda University) (submittedVersion)
- Rare & Special e-Zone (The Hong Kong University of Science and Technology) (submittedVersion)
- Funders
- National Institute on Aging (P01AG030128, R01AG039452, R01AG027924, R37AG023084, P50AG005142, RF1AG046205, R37AG23084, R01AG046205, R01AG035355, P50AG016574)
- National Institute of Neurological Disorders and Stroke (R37NS034467, R00-NS07743, R37NS34467, P01NS074969)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
- Keywords
- PICALM, amyloid-beta, blood-brain barrier, transcytosis, amyloid-beta clearance, Alzheimer's disease, brain endothelium, clathrin-mediated endocytosis, LRP1, Rab5, Rab11, cognitive impairment, iPSC-derived endothelial cells, adenoviral gene transfer
- MeSH terms
- Alzheimer Disease, Animals, Blood-Brain Barrier, Capillaries, Cerebral Cortex, Endothelium, Vascular, Homeostasis, Humans, Metabolic Clearance Rate, Amyloid beta-Peptides, Mice, Knockout, Monomeric Clathrin Assembly Proteins, Pluripotent Stem Cells, Mice, Transcytosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
